R
Raf Schepers
Researcher at National Institute on Drug Abuse
Publications - 8
Citations - 604
Raf Schepers is an academic researcher from National Institute on Drug Abuse. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 3, co-authored 3 publications receiving 361 citations.
Papers
More filters
Journal ArticleDOI
Methamphetamine and Amphetamine Pharmacokinetics in Oral Fluid and Plasma after Controlled Oral Methamphetamine Administration to Human Volunteers
Raf Schepers,Jonathan M. Oyler,Robert E. Joseph,Edward J. Cone,Eric T. Moolchan,Marilyn A. Huestis +5 more
TL;DR: Perceived advantages of oral fluid for verifying METH exposure compared with urine include simpler specimen collection and reduced potential for adulteration, but urine offers higher analyte concentrations and a greater window of detection.
Journal ArticleDOI
Plasma and Oral Fluid Pharmacokinetics and Pharmacodynamics after Oral Codeine Administration
Insook Kim,Allan J. Barnes,Jonathan M. Oyler,Raf Schepers,Robert E. Joseph,Edward J. Cone,Diana Lafko,Eric T. Moolchan,Marilyn A. Huestis +8 more
TL;DR: Oral fluid testing is a useful alternative matrix for monitoring codeine exposure with a detection window of 7-21 h for single doses, depending on cutoff concentrations, but because of high variability, oral fluid codeine concentrations did not reliably predict concurrent plasma concentrations.
Journal ArticleDOI
Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
Stijn P. Andeweg,Brechje de Gier,Dirk Eggink,Caroline van den Ende,Noortje M van Maarseveen,Lubna Ali,B. Vlaemynck,Raf Schepers,Susan Hahné,Chantal B.E.M. Reusken,Hester E. de Melker,S. van den Hof,Mirjam J. Knol +12 more
TL;DR: In this paper , the authors employed a test-negative design on S-gene target failure data from community PCR testing in the Netherlands from 22 November 2021 to 31 March 2022 (n = 671,763).
Journal ArticleDOI
Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021
Jantien A. Backer,Dirk Eggink,Stijn P. Andeweg,Irene K. Veldhuijzen,Noortje M van Maarseveen,Klaas Vermaas,B. Vlaemynck,Raf Schepers,S. van den Hof,Chantal Bem Reusken,Jacco Wallinga +10 more
TL;DR: The SARS-CoV-2 Omicron variant has a growth advantage over the Delta variant because of higher transmissibility, immune evasion or shorter serial interval, and within households, the mean serial interval for SGTF cases was 0.2–0.6 days shorter than for non-SGTF cases.
Journal ArticleDOI
Increased risk of infection with SARS-CoV-2 Omicron BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022
Dirk Eggink,Stijn P. Andeweg,Harry Vennema,Noortje M van Maarseveen,Klaas Vermaas,B. Vlaemynck,Raf Schepers,Arianne B van Gageldonk-Lafeber,S. van den Hof,Chantal B.E.M. Reusken,Mirjam J. Knol +10 more
TL;DR: It is suggested that vaccine- or infection-induced immunity against SARS-CoV-2 infections is less effective against the Omicron than the Delta variant.